 | |
| Names | |
|---|---|
| Preferred IUPAC name N1-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N′1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| Other names XL880; EXEL-2880; GSK1363089; GSK089 | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.158.129 |
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C34H34F2N4O6 | |
| Molar mass | 632.665 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered byExelixis and is under development byGlaxoSmithKline.[2] About 10 Phase II clinical trials have been run.[3] As of October 2015[update] it appears development has been discontinued.[4]
Foretinib is aninhibitor of the kinase enzymesc-Met andvascular endothelial growth factor receptor 2 (VEGFR-2).[5]
